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Abstract: Schizophrenia Spectrum Disorder (SSD) is a chronic psychiatric disorder with a modest
treatment outcome. In addition, relapses are commonplace. Here, we sought to identify factors that
predict relapse latency and frequency. To this end, we retrospectively analyzed data for individuals
with SSD. Medical records of 401 individuals with SSD were analyzed (mean age: 25.51 years; 63.6%
males) covering a five-year period. Univariate and multivariate Penalized Likelihood Models with
Shared Log-Normal Frailty were used to determine the correlation between discharge time and
relapse and to identify risk factors. A total of 683 relapses were observed in males, and 422 relapses
in females. The Relapse Hazard Ratio (RHR) decreased with age (RHR = 0.99, CI: (0.98–0.998)) and
with participants’ adherence to pharmacological treatment (HR = 0.71, CI: 0.58–0.86). In contrast,
RHR increased with a history of suicide attempts (HR = 1.32, CI: 1.09–1.60), and a gradual compared
to a sudden onset of disease (HR = 1.45, CI: 1.02–2.05). Gender was not predictive. Data indicate
that preventive and therapeutic interventions may be particularly important for individuals who are
younger at disease onset, have a history of suicide attempts, have experienced a gradual onset of
disease, and have difficulties adhering to medication.
Keywords: schizophrenia spectrum disorder; relapse; predictions; treatment adherence
1. Introduction
Even 100 years after Kreapelin’s seminal work on the phenomenon of dementia praecox,
schizophrenia (schizophrenia spectrum disorder; SSD) remains enigmatic in regards to
its multiform etiology, its symptomatology, its uncertain disease progress, the modest
treatment outcomes, and the issue of comorbidities such as tobacco use disorder, obesity,
and diabetes [1–3]. The term schizophrenia spectrum disorder covers a broad range of
different symptoms and not all individuals with SSD display all the symptoms and not all
symptoms are simultaneously present. Typically, individuals with SSD show disorgani-
zation in formal thoughts and language, hallucinations, delusions, catatonic symptoms,
dysfunctions in affect and mood, self-disorder, somatic symptoms, and neurocognitive
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impairments. Up to 50% of individuals with SSD display functional impairments that
increase the risk of permanent unemployment and inability to build and maintain stable
relationships [2,3].
Olabi et al. [4] further stressed that SSD is not a uniform disorder and that interindivid-
ual variance of the disorder was also mirrored in the high variance of results among studies.
Despite progress in describing the brain morphology of individuals with SSD, dis-
tinctive features identified in imaging studies do not appear to be associated with either
the incidence or prevalence of relapses [3,5,6]. On this point, in their exploratory quan-
titative meta-analysis of structural neuroimaging studies, Chee et al. [7] concluded that
neuroanatomical indices that are predictive of relapses in individuals with SSS have yet
to be identified. It follows that the prediction of relapses and the time interval between
recovery and relapse cannot rely on imaging studies, but must do so on observational
evidence. Eisner et al. [8] reported that relapse in psychosis is a common phenomenon
among individuals with SSD. Furthermore, relapses are associated with higher risks of
unemployment, long-term deterioration, and suicidal behavior. Given this, detecting early
signs and predictors of a future relapse deserve careful attention, and this holds particularly
true for Iran, where research on this topic is virtually nonexistent.
Leucht et al. [3] identified the following common early signs of relapse: Restlessness,
sleep disorders, tension, issues at work, feelings of not being understood and being stressed,
low degree of satisfaction, social withdrawal, cognitive impairments such as in attention
and memory, increased religious thoughts, losing control of oneself, hallucinations, external
voices, and thoughts taking control. Emsley et al. [9] concluded from their narrative
review that the risk of relapses was higher if medication was interrupted, irrespective
of the number of previous psychotic episodes. In addition, and against expectations,
a longer treatment period prior to medication interruption did not reduce the odds of
relapse; relapses may occur shortly after discontinuing medication with either no or several
warning signs. In 1995, Jablensky [10] reviewed the state-of-the-art and identified six factors
associated with positive and negative outcomes: Odds of relapse were greater when the
individual with SSD was single, divorced, male, and living in a family environment with
high expressed emotion (factor: Sociodemographic and family-related data), when social
withdrawal was high and adjustment problems were observable in adolescence (factor:
Premorbid personality and adjustment problems), when relapses were more frequent and
longer (factor: Preceding illness characteristics), when the onset of disease was either very
gradual or abrupt (factor: Onset characteristics), when negative symptoms and acoustic
hallucinations prevailed (factor: Initial clinical frame), and when cannabis use was reported
(factor: Other characteristics). To conclude, Jablensky’s overview summarized a broad
range of possible factors consistent with what had been already observed in the mid-
70s [11]. A total of 47 different predictors were identified and these predictors explained
38% of the variance in relapses, which leaves 62% unexplained. The same report also notes
that 60% of inpatients with SSD suffered from a relapse after their first hospitalization.
Lecomte et al. [12] conducted a metareview of 31 meta-analyses summarizing the
results from 3044 papers on relapse predictors. For protective factors, they concluded there
was moderate to strong evidence for antipsychotic medication in adults, family interven-
tions, social skills training, and interventions focusing on recovery management skills.
Eisner et al. [8] conducted in-depth interviews with individuals with SSD to detect, beyond
indicators related to sociodemographic factors or medication, possible early cognitive, emo-
tional, or behavioral signs of an imminent relapse. Their interviews identified the following
signs: Increased indecisiveness about insignificant choices; poor multitasking; thought
interference; disturbance of receptive speech; increased stress reactivity; hypersensitivity
to sounds; visual problems such as straight things appearing crooked and double vision;
thought perseveration; overly distracted by stimuli; disturbances of olfactory, gustatory,
and tactile perceptions; micropsia and macropsia; near- or tele-vision; shapes appearing
different or distorted; decreased ability to distinguish between ideas and perceptions or be-
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tween fantasy and true memories; derealization; thought blockages and thought pressure;
and slowed-down thinking.
Others [3,10,13,14] have reported that the likelihood of suffering from SSD is greater
when first to third degree relatives have been diagnosed with SSD.
Mortensen et al. [13] showed that the odds of suffering from SSD are greater when a
person grows up in an urban area (place of birth effect), and when a person was born in
the spring but not in the autumn (season effect).
Lastly, David and Prince [15] concluded in their review that the association between
head traumas and the occurrence of SSD is weak and that results are contradictory.
Currently there is some but modest and inconsistent evidence that sociodemographic
factors (e.g., younger age, male gender, living in an urban area, and being single, born in the
spring), illness-related factors (e.g., slow and prolonged prodromal phase, non-adherence
to medication, history of SSD in first to third degree relatives), both typical (thought
interference, increased stress reactivity, thought perseveration; see Eisner et al. [8]) and
atypical symptoms (e.g., social withdrawal, symptoms of depression, issues at workplace)
can all increase the odds of a relapse. We took these observations into consideration and
introduced age, sex, marital status, mode of disease onset, medication adherence, place
and season of birth, history of SSD among relatives, history of head traumas, and suicide
attempts as possible factors affecting the odds and latency of relapses.
In regards to the situation in Iran, the prevalence of SDD ranges from 05% to 0.6%
to 0.89%, depending on the diagnostic criteria (lower prevalence rates based on the DSM-
IV than on the DSM-5), and the date of the survey (more recent studies report higher
prevalence rates [16]). Mohammadi et al. [17] assessed 25,180 Iranian adults via face-to-face
clinical interviews and reported a prevalence rate of 0.89% for SSD.
Furthermore, in regards to research on relapse prediction in Iran, to our knowledge,
only Rahmati et al. [14] have considered this. This might not be surprising, given the low
prevalence rate of SDD compared to the prevalence rates for anxiety disorders (8.35%),
mood disorders (4.29%), and psychiatric disorders in general (10.81%) [17]. However, given
a population of about 86 million, statistically 765,400 individuals might be suffering from
SSD. Rahmati et al. [14] analyzed medical records of 159 individuals with SSD (mean age:
21.52 years; age range: 10 to 43 years) over a period of about six years. The best predictors
for a first relapse were a younger age at disease onset, being male, being single, a gradual
and prolonged prodromal phase, and a family member with a history with SSD. Two and
more relapses were predicted by these factors and by the occurrence of a preceding relapse.
Taken together, in regards to the current situation for SSD and the risk of relapses in
Iran, research is particularly scarce. To counter this, the present study reviewed retrospec-
tively the medical records of 401 individual with SSD over a period of about 60 months in
order to identify factors predicting a relapse and the latency of relapses.
Based on previous studies [9,12,14] our first hypothesis was that a younger age at
disease onset, low adherence to prescribed medication, being male, and a gradual and
prolonged prodromal disease phase would predict the odds and number of relapses.
Following Eisner et al. [8], our second hypothesis was that the occurrence of suicide
attempts would predict the odds and number of relapses.
We believe that the findings from this study could be of clinical and practical impor-




This is a retrospective cohort study based on medical records of individuals with SSD
who were admitted at least once to the Farabi Hospital of Kermanshah (Kermanshah, Iran)
between 2015 and 2019. We analyzed anonymized medical records of all individuals with
SSD, who were readmitted at least once. Participants signed a written informed consent
and the Research Department of the Kermanshah University of Medical Sciences (KUMS;
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Kermanshah, Iran) approved the present study (registration code: IR.KUMS.REC.1398.329),
which was performed in accordance with the seventh and current revision [18] of the
Declaration of Helsinki.
2.2. Data Collection Based on the Medical Records: Variables of Interest
The following information was extracted from the medical records both for the first
and all consecutive hospitalizations.
Sociodemographic information: Age; sex; civil status (single; married; divorced/
widowed); place of birth (rural vs. urban area); season of birth (spring; summer; autumn;
winter); and employment status (employed vs. unemployed).
SSD-related and illness-related information: Mode of disease onset (gradual vs. acute
onset); adherence to prescribed medication (yes vs. no; if medications were either an-
tipsychotics, anticonvulsants, or a combination of these); substance abuse as secondary
comorbidity (yes vs. no); number of relapse(s); time lapse(s) between the current re-
hospitalization and the last discharge; suicide attempt(s) (yes vs. no); family history of SSD
(first to third degree relatives: yes vs. no); and history of head trauma (skull fracture before
disease onset or coma after the trauma: yes vs. no).
2.3. Definition of Relapse
Rehospitalization was used as a proxy for relapse and we were interested in the
number of such relapses and the timing between hospitalization admission. We followed
Rahmati et al. [14] in defining a relapse as the first SSD-related re-hospitalization of an
individual with SSD after discharge. Outcome measures were the number of relapses and
the time interval between initial discharge and relapse(s).
2.4. Definition of Medication Adherence
Medication non-adherence was defined as the gap between the patient’s reported
medication intake and the prescribed medication intake [19,20].
2.5. Sample Selection
Between 2014 and 2019, 902 records of inpatients with SSD were stored in the hospital
archive. The inclusion criteria were: 1. Diagnosis of SSD, as ascertained by a trained and
experienced psychiatrist or clinical psychologist and based on the DSM 5 [21]. 2. Age
between 18 and 65 years. 3. General signed written informed consent. 4. At least one
readmission on record. The exclusion criteria were: 1. Wrong diagnosis. 2. Unable or
unwilling to answer some questions asked either on the phone or face-to-face in order to
fill gaps in information missing from the medical records. 3. No readmission. As shown
in Figure 1, of the medical records of 902 inpatients with SSD, 401 records (44.46%) were
analyzed and 501 (55.54%) were excluded.
2.6. Statistical Analysis
For quantitative variables, we used means and standard deviations, while qualitative
variables were used in order to analyze frequency and percentage. The variables were
first univariate and then entered in a multivariate analysis in which the variables with
p-value < 0.05 were introduced into the multivariate survival analysis. For data analysis,
the recurrent event model was used employing Penalized Likelihood in software R.3.5.3
(R Foundation for Statistical Computing, Vienna, Austria) and “frailty pack”. Shared Log-
Normal Frailty was used to analyze elapsed time to recurrent relapses. In this study, the
time from onset of disease to onset of recurrent readmissions was recorded for each patient
in days. The significance level was set at 0.05 for studying Adjusted Hazard Ratio.
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3. Results
3.1. General Pbservations
Table 1 reports the descriptive statistical indices of sociodemographic and illness-
related information, both for the entire sample and separately for gender.
Data of 401 individuals with SSD were analyzed and 255 (63.6%) were males (mean
age: 37.56 years) and 146 (36.4%9) were females (mean age: 38.33 years). The numbers of
male and female readmissions were 683 and 422 cases, respectively, as shown in Table 1.
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Table 1. Distribution of the characteristics, separately by gender.
Variable Total Male Female
N (%) 401 (100) 255 (63.59) 146 (36.40)
M (SD) M (SD) M (SD)
Age 37.81 (9.90) 37.56 (10.06) 38.33 (9.62)
Age at onset of SSD
(years) 26.24 (9.05) 25.64 (8.70) 27.29 (9.56)
Frequency (%) Frequency (%) Frequency (%)
Marital status
Married 104 (25.9) 63 (24.7) 41 (28.1)
Single 250 (62.3) 167 (65.5) 83 (56.8)
Divorced/widowed 47 (11.7) 25 (9.8) 22 (15.1)
Place of birth
Urban 279 (69.6) 186 (72.9) 93 (63.7)
Rural 122 (30.4) 69 (27.1) 53 (36.3)
Employment status Employee 98 (24.4) 92 (36.1) 6 (4.1)
Unemployed 303 (75.6) 163 (63.9) 140 (95.9)
Substance Abuse
No 306 (76.3) 170 (66.7) 136 (93.2)
Yes 95 (23.7) 85 (33.3) 10 (6.8)
History of head trauma No 380 (94.8) 239 (93.7) 141 (96.6)
Yes 21 (5.2) 16 (6.3) 5 (3.4)
Family history of
schizophrenia
No 372 (92.8) 236 (92.5) 136 (93.2)
Yes 29 (7.2) 19 (7.5) 10 (6.8)
Mode of Onset
Acute 41 (10.2) 28 (11) 13 (8.9)
Gradual 360 (89.8) 227 (89) 133 (91.1)
Medication Adherence
Non-Adherence 234 (58.4) 149 (58.4) 85 (58.2)
Adherence 167 (41.6) 106 (41.6) 61 (41.8)
Season of Birth
Spring 120 (29.9) 74 (29) 46 (31.5)
Summer 123 (30.7) 79 (31) 44 (30.1)
Autumn 69 (17.2) 47 (18.4) 22 (15.1)
Winter 89 (22.2) 55 (21.6) 34 (23.3)
History of suicide
attempt
No 325 (81.0) 203 (79.6) 122 (83.6)
Yes 76 (19.0) 52 (20.4) 24 (16.4)
Number of relapses
One to two relapses 222 (55.4) 144 (56.5) 78 (53.4)
Three to four relapses 114 (28.4) 70 (27.5) 44 (30.1)
Five to eleven relapses 65 (16.2) 41 (16.1) 24 (16.4)
3.2. Relapses
The median time to readmission was 238 days for individuals who were medication
adherent, while for those with medication non-adherence readmission time was 106 days
(p < 0.001; see Table 1). Almost all individuals with SSD had readmissions within a year
after discharge (Figure 2).
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With a greater age of disease onset, the Hazard Ratio of the disease relapse reduced,
which was only 0.01 times (HR = 0.99, 95%, CI: 0.981–0.998).
Compared to a sudden onset, gradual onset increased the Hazard Ratio (HR = 1.45,
95%, CI = 1.02–2.05). A history of suicide attempts had a 1.32-fold higher risk of readmission
to hospital (HR = 1.32, 95%, CI = 1.09–1.60).
The risk of subsequent relapses was 0.71-fold less for individuals with SSD with
medication adherence than for those with no medication adherence (HR = 0.71, 95%,
CI = 0.58–0.86). On the other hand, gender, marital status, employment status, substance
abuse, head t auma, family history of schizophrenia, and season of birth had no effect on
the Hazard Ratio of relapse (Table 2).
Table 2. Crude and adjusted Shared Log-Normal Frailty model parameter estimates.
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gradual 1.48 (1.05–2.08) 1.45 (1.02–2.05) 0.0384
Medication Adherence
(non-adherence) 1









Yes 1.49 (1.05–2.11) 1.32 (1.09–1.60) 0.0314
Frailty parameter
Sigma Square = 0.08
SE = 0.01
p < 0.001
* HR: Hazard Ratio. In all variables the reference class is in parentheses.
4. Discussion
The key findings of the present study were that over a period of 60 months, relapses
were very common among individuals with SSD and that low adherence to medication,
reported suicide attempts, a gradual onset of disease, and a younger age at disease onset all
predicted a higher relapse ratio and a shorter relapse interval. In contrast, gender, marital
status, employment status, substance abuse, head trauma, family history of schizophrenia,
and season of birth did not predict the odds of relapses and/or relapse latency. The present
results add to the current literature in an important way in that both treatment medication
adherence and lack of suicide attempts were important factors in lower relapse rates and
longer relapse intervals. While the pattern of results might be discouraging, we also note
that it matches with what we know so far from statistical models predicting relapses in
psychosis. Thus, Sullivan et al. [5] concluded in their systematic review that due to the
lack of high quality evidence, it was impossible to formulate recommendations in regards
to possible predictors. Similarly, it appears that evidence from neuroimaging has not
generated robust predictors [6].
Two hypotheses were formulated and each of these is considered in turn.
Our first hypothesis was that being at a younger age at disease onset, low adherence
to prescribed medication, male gender, and a gradual and prolonged prodromal phase of
disease would predict the odds and number of relapses. This hypothesis was not, however,
fully supported. While a lack of adherence to medication, younger age at disease onset,
Int. J. Environ. Res. Public Health 2021, 18, 546 9 of 13
and a gradual onset of disease did all predict a shorter time interval between relapses,
an independent effect of gender did not reach statistical significance. In this respect the
present results are at odds with previous findings [9,12,14]. The evidence available to
us from this study is insufficient to clarify why gender was not a predictor for relapses.
However, Table 1 shows that while the gender ratio was 2(m):1(f) and thus very similar to
the ratios reported in previous studies, in the present sample, descriptively, the females
were more often divorced or widowed, more often unemployed, and more often reported a
gradual onset of disease. In contrast, no descriptive differences in gender distributions were
observed for the number of relapses or for medication adherence. Overall, the statistical
analysis suggests that either there was in fact no gender difference or that other factors had
a higher statistical power.
Medication adherence emerged in this study as a predictor of fewer relapses and
longer inter-relapse intervals. Adherence to medication treatment is a therapeutic issue.
The scientific community proposes two interventions (or their combination) for improving
adherence to medication: Psychoeducation and long acting injectables (LAIs as opposed to
oral antipsychotics (OAPs)). With respect to psychoeducation, Barkof et al. [22] concluded
in their review that interventions with more sessions, sessions with a focus on medication
adherence, and pragmatic interventions that focus on attention and memory problems
improved adherence, while motivational interviewing did not appear to increase adherence.
Similarly, Zhao et al. [23] showed that brief psychoeducational sessions (10 or less sessions)
appeared to reduce the relapse rate in the medium term and to increase the medication
compliance in the short term. Sendt et al. [24] showed in their systematic review that a
patient’s positive attitude to medication and illness insight were associated with higher
medication adherence. Among younger patients, a therapeutic relationship and social
support had positive impacts on adherence to prescribed medication. In contrast, Hegerdüs
and Kozel [25] found no association between adherence to therapy and adherence to medi-
cation. Similarly, Gray et al. [26] showed that adherence training as an adjunctive treatment
reduced patients’ symptom severity but did not alter their attitudes to medication ad-
herence. Lastly, Petry et al. [27] showed that financial inducements (USD 50 or more per
week) for a longer duration yielded higher medication treatment adherence. In regards to
LAIs, results from systematic reviews and meta-analyses showed that LAIs were superior
to OAPs regarding hospitalization rate and all-cause discontinuation of medication but
were not superior regarding the risk of hospitalization, time in hospital [28], or number of
relapses [29] in RCTs, which by definition are less representative of real-world patients in
naturalistic studies. Compared to second-generation OAPs, LAIs had lower relapse rates, a
longer time to relapse, and fewer hospital days, but also a higher occurrence of extrapyra-
midal symptoms and prolactin-related symptoms [30]. In this context, second generation
LAIs had similar effects to first generation LAIs, but the former dramatically increased
serum prolactin concentrations, weight, and BMI (Body Mass Index) [31]. When compared
to placebo, LAIs showed advantages with respect to psychosocial functioning, but this
was not the case when compared to OAPs [32]. Compared to OAPs, LAIs reduced the
percentage but not the absolute number of hospitalizations [33], while LAIs increased
symptoms of dyskinesia [34].
Taken together, previous studies and present data showed that medication adherence
appears to be an important protective factor for relapses, though when using second
generation LAIs in particular the dramatic side effects such as weight gain, increased
prolactin concentrations, and tardive dyskinesia should be carefully considered.
Our second hypothesis was that suicide attempts would predict the occurrence of
relapses and shorter relapse intervals, and these expectations were confirmed. Thus, the
present findings are in accord with previous results [8].
We believe that suicide attempts as a relapse risk demands particular attention. By def-
inition, suicide is the decision deliberately to end one’s life. Suicide has become one of
the leading causes of death in the world [35]. Furthermore, suicide attempts may have
long-lasting negative consequences both for the individuals concerned and for those in
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their social worlds, including family members, workplace colleagues, and witnesses to the
suicide attempt [35]. Importantly, when an individual has strong suicidal ideations, death
appears to be the only solution to a subjectively perceived unbearable life situation [36].
Several factors have been advanced to predict suicide attempts (see [37,38] for exten-
sive discussions). Here, we emphasize social and behavioral dimensions.
Nazarzadeh et al. [39] identified loneliness and weak family ties as stronger predictors
of suicidal behavior than co-varying economic factors. Early maladaptive schemas of
emotional deprivation, social isolation, shame, and abandonment were related to a history
of suicide attempts among patients with major depressive disorders [40]. Among women,
reporting failed self-immolation, feelings of being trapped in the husband’s adverse fam-
ily system, stress related to marital life, copycatting, and absence of social support were
identified as key factors [41].
In addition, attempting and committing suicide implies behavior-inducing cognitions
such as emotional stoicism, sensation-seeking, pain tolerance, and lack of fear of death
(Deshpande, et al. [42]). Other social and behavioral factors include a state of over-arousal,
along with social withdrawal and perceived burdensomeness [38], thwarted belongingness
(i.e., the belief that one does not belong to a social group, or believes oneself to be unimpor-
tant and useless to other people) [43], and feelings of defeat, social rejection, entrapment,
humiliation, and subjectively perceived low social support [44]. In this context, and in
regards to the situation in Iran, individuals with SSD and their caregivers are frequently
stigmatized and can often experience social rejection, covert and open hostility and aggres-
sion, and humiliation [45,46]. Given this, individuals with SSD and their caregivers and
families risk further stigmatization, social isolation, and less access to health care [47].
We do not have from the present study the evidence to specify the psychological or
physiological mechanisms that may underlie suicidal behavior. However, counseling and
treatment of persons with SDD should pay particular attention to suicidal ideation, in
particular to the patient’s quality and quantity of social interactions. This is especially
important given the failure thus far of evidence from imaging studies to provide satisfactory
predictors of either relapses or suicidal behavior [5,6]. Similarly, although 47 different
predictors together explain about 38% of the variance in relapses and thus 62% of the
variance remains unexplained [11], future studies should seek to identify other robust
predictors of relapse and the means to improve the social competences to form and maintain
stable social relationships of people with SSD.
The novelty of the study results should be balanced against the following limitations.
First, rehospitalization is usually precipitated by an increase in positive symptoms of
psychosis while other important domains of behavior and functioning such as cognitive
performance, social interactions with family members, co-workers, neighbors, and health
care providers, along with the health care system and the quality of care received after
discharge from hospital, were not assessed. Likewise, secondly, the evidence available
from the study cannot provide a robust and comprehensive answer to the question of
whether SSD should be considered a neurodegenerative disease or instead a failed neuronal
regenerative disease with the possibility of neuronal repair and regeneration or both [2].
Thirdly, given our statistical approach, only the records of participants with at least one
rehospitalization were entered in the equations. Given this, it is possible that the pattern
of results may be biased or imprecise. In this regard, fourthly, the pattern of results
may be biased in two ways: (a) By definition a retrospective cohort study relies on the
quality of medical records and (b) medical records and other SSD-related information
are not available in cases where rehospitalization did not occur in the Farabi Hospital of
Kermanshah (Kermanshah, Iran), but in another psychiatric hospital. Fifthly, the study did
not address an additional but key question from the point-of-view of individuals with SSD
and their caregivers: How to improve the quality of life of people with SSD. Besides the
strategies for improving treatment adherence discussed above, regular physical activity
appears to have a beneficial effect on aspects of SSD and in particular on unpleasant side-
effects of antipsychotics such as weight gain and sedentary behavior [48–55]. Furthermore,
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there is a need for early detection and treatment of SSD symptoms so as to keep the quality
of life in individuals with SSD as stable as possible [56].
5. Conclusions
Among a large sample of Iranians with SDD, younger age at disease onset, non-
adherence to medication, a history of suicide attempts, and a gradual onset of disease all
predicted higher hospital readmission and a shorter readmission interval after the initial
admission. Given this, counseling and treatment should focus on patients distinguished by
these risks. Only non-adherence can be addressed by preventive measures but it is hoped
that these results will aid clinicians in their quest to improve treatment adherence.
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